{
    "clinical_study": {
        "@rank": "63665", 
        "acronym": "PRROTECT", 
        "arm_group": [
            {
                "arm_group_label": "omalizumab group", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive omalizumab."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will perform a double blind, placebo controlled clinical trial with Xolair\n      (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut\n      allergy. The investigators will determine if pretreatment with anti-IgE mAb\n      (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer\n      desensitization."
        }, 
        "brief_title": "Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peanut Allergy", 
            "Food Allergy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypersensitivity", 
                "Food Hypersensitivity", 
                "Peanut Hypersensitivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "36 subjects will receive Xolair, and 8 subjects will receive placebo.  The study will occur\n      at 4 sites:  Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford\n      University and Lurie Children's Hospital.\n\n      Patients will be pre-treated with Xolair or placebo before rapid oral peanut\n      desensitization.  Patients will continue to receive Xolair during the 8 subsequent weeks of\n      desensitization, receiving their final dose of Xolair one week after reaching the highest\n      tolerated dose of peanut."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25\n             years old.\n\n          -  Sensitivity to peanut allergen will be documented by a positive skin prick test\n             result (6 mm diameter wheal or greater)\n\n          -  ImmunoCAP IgE level to peanut > 10 kU/L.\n\n          -  Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food\n             challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.\n\n        Exclusion Criteria:\n\n          -  Subjects with a total IgE at screening of < 50 kU/L > 2,000 kU/L.\n\n          -  Positive reaction to the placebo on DBPCFC.\n\n          -  Previous reaction to omalizumab.\n\n          -  Subjects having a history of severe anaphylaxis to peanut requiring intubation or\n             admission to an ICU, frequent allergic or non-allergic urticaria, or history\n             consistent with poorly controlled persistent asthma, or gastrointestinal or\n             gastroesophageal disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781637", 
            "org_study_id": "Peanut 002"
        }, 
        "intervention": [
            {
                "arm_group_label": "omalizumab group", 
                "description": "subcutaneous injection", 
                "intervention_name": "Omalizumab", 
                "intervention_type": "Drug", 
                "other_name": "Xolair"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "subcutaneous injection", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Omalizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Xolair", 
            "omalizumab", 
            "peanut", 
            "oral desensitization"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "safar.inquiry@stanford.edu", 
                    "last_name": "Tony Trela"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": {
                    "last_name": "Kari C Nadeau, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "MVAZQUEZ@LURIECHILDRENS.ORG", 
                    "last_name": "Maripaz Vazquez, BSN", 
                    "phone": "312-227-6474"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Lurie Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Jacqueline Pongracic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Division of Immunology, Children's Hospital Boston"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "ROONEYC@EMAIL.CHOP.EDU", 
                    "last_name": "Courtney B Rooney", 
                    "phone": "267-426-8657"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }, 
                "investigator": {
                    "last_name": "Jonathan Spergel, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of Omalizumab in Oral Peanut Desensitization", 
        "overall_contact": {
            "email": "sara.little@childrens.harvard.edu", 
            "last_name": "Sara Little", 
            "phone": "617-355-6127"
        }, 
        "overall_contact_backup": {
            "last_name": "Lynda C Schneider, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Children's Hospital Boston", 
                "last_name": "Lynda C Schneider, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children' Hospital Boston", 
                "last_name": "Andrew MacGinnitie, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Stanford University", 
                "last_name": "Kari Nadeau, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Children's Hospital of Philadelphia", 
                "last_name": "Jonathan Spergel, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Lurie Children's Hospital", 
                "last_name": "Jacqueline Pongracic, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The ability of omalizumab-treated subjects to successfully complete the build-up phase of peanut, and tolerate daily 4,000 mg doses of peanut flour after discontinuing omalizumab.", 
            "safety_issue": "Yes", 
            "time_frame": "14 wks after the start of oral peanut desensitization (wk 26 of study)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781637"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Children's Hospital Boston", 
            "investigator_full_name": "Lynda Schneider", 
            "investigator_title": "Associate Professor, Harvard Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The ability of subjects to tolerate an oral dose of 4,000 mg peanut.", 
            "safety_issue": "Yes", 
            "time_frame": "8 wks after the start of oral peanut desensitization (study wk 20)."
        }, 
        "source": "Children's Hospital Boston", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Children's Hospital of Philadelphia", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Stanford University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ann & Robert H Lurie Children's Hospital of Chicago", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Children's Hospital Boston", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}